
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is poised for continued growth as a leader in TMS commercialization due to its innovative technology and strategic investments in mental health networks. With 11 consecutive quarters of profitability and expected growth through 2026, the company has a solid financial foundation and potential for expansion into new indications and partnerships. While competition and regulatory challenges may pose risks, BrainsWay's strong market demand and successful business strategy suggest a positive outlook for the company.
Bears say
BrainsWay is positioned for long-term success due to its strong financial performance, growing recurring revenue model, and expanding market opportunities, including the anticipated commercial entry of COMP360 psilocybin therapy. Additionally, the company's intellectual property portfolio and real-world evidence support the effectiveness of its Deep TMS platform technology. While competition from alternative therapies may arise, the continued support from key investors like Valor Equity Partners provides a solid foundation for future growth and success.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares